A recent study using real-world data from the TriNetX health research network found that patients with treatment-resistant depression who received esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) had lower risks of death, hospitalizations, and relapse compared to those who received esketamine with a selective serotonin reuptake inhibitor (SSRI).

Both groups had low rates of mortality, hospitalizations, depression relapses, and suicide attempts, but the esketamine plus SNRI group showed statistically significant higher survival rates over 5 years. The findings emphasize the importance of selecting the appropriate antidepressant partner for esketamine and tailoring treatment to an individual patient profile.

Source: JAMA Psychiatry